RNTX
Rein Therapeutics, Inc.
NASDAQ · Healthcare · Medical - Pharmaceuticals · US
$0.80
+1.37%Next report
Analyst consensus
- Next report date
- Nov 13, 2026
- EPS estimate
- -$0.10
- Revenue estimate
- —
Latest reported
- Last report date
- Aug 14, 2026
- EPS actual
- -$0.10
- EPS estimate
- -$0.17
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 4
- EPS misses (12Q)
- 8
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -73.4%
- Revenue beats (12Q)
- —
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $6.00
- PT range
- $4.00 – $8.00
- Analysts
- 2
2 Buy0 Hold0 Sell
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 14, 2026 | -$0.17 | -$0.10 | Beat 41.18% | — |
| May 15, 2026 | -$0.49 | -$0.19 | Beat 61.22% | — |
| Mar 26, 2026 | -$0.24 | -$1.22 | Miss -408.33% | — |
| Nov 14, 2025 | -$0.24 | -$0.21 | Beat 12.50% | — |
| Aug 14, 2025 | -$0.22 | -$0.28 | Miss -27.27% | — |
| Apr 7, 2025 | -$0.14 | -$0.26 | Miss -85.71% | — |
| Dec 31, 2024 | -$0.46 | -$1.89 | Miss -310.68% | — |
| Aug 14, 2024 | -$0.25 | -$0.45 | Miss -80.00% | — |
| Mar 31, 2024 | -$0.14 | -$0.86 | Miss -512.00% | — |
| Dec 31, 2023 | -$0.16 | -$1.54 | Miss -840.03% | — |
| Sep 30, 2023 | -$0.20 | -$0.40 | Miss -101.16% | — |
| Jun 30, 2023 | -$0.40 | -$0.39 | Beat 1.62% | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 13, 2026